Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

1H soft; Behring solid, Seqirus soft, Vifor strength

CSL Ltd
3:27pm
February 11, 2025
1H results were a bit soft, with FX denting bottom line growth and vaccine sales pulling down top line gains, although constant currency (cc) margins held and OCF was strong. Divisional sales were mixed, with continued strong plasma collections propelling Behring sales (+10%) and Vifor showing surprising strength (+6%), while Seqirus failed to overcome weak immunisations in the US. Notably, Behring GPM expanded above expectations (+170bp, 51.7%), owing to lower cost/litre and numerous other initiatives, with the return to pre-COVID margins (c58%) still targeting FY27/28. FY24 guidance (cc NPATA +10-13%) was reaffirmed, implying a very strong 2H (+19% at mid-point), which looks achievable given Vifor’s growth and pandemic avian influenza contracts for Seqirus, with overall double-digit earnings growth continuing to be expected over the medium term. Our PT moves to A$329.26 on modest earnings changes and FX. Add.

Phase 3 clinical trial begins and coverage ceases

Tissue Repair
3:27pm
February 11, 2025
TRP has recruited the first patient into its US Phase 3 trial for chronic venous leg ulcers. TRP is also pursuing a medical device application in addition to the traditional drug path which according to management may see an earlier approval. TRP finished with cash of A$14.4m at 2Q25. We are continually reviewing our Healthcare coverage list. At this time we will remove TRP from our Keeping Stock coverage.

3Q25 update

Macquarie Group
3:27pm
February 11, 2025
MQG’s 3Q25 update disclosed that NPAT for the first nine months (FY25 YTD) was broadly in-line with the pcp. We note MQG’s short-term outlook commentary has not changed from its last update, but the market before today was factoring in 8% FY25 NPAT growth. This implies the company needs a relatively strong Q4 to get near market expectations. We lower our MQG FY25F EPS by 6%, with nominal changes to our future year forecasts. Our PT (~A$218) is largely unchanged with our earnings changes offset by a valuation roll-forward. MQG is a quality franchise, but we think the recent strength in its share price is arguably unjustified, and we see the stock as fair value trading on ~23x FY25F earnings. We maintain a HOLD rating.

Hitting positive cashflow

Clever Culture Systems
3:27pm
February 11, 2025
Clever Culture Systems (CC5) has achieved cash flow break-even for operating activities in 2Q25 in line with previous guidance. Further to this, management has guided to the next two quarters being operating cashflow positive. CC5’s strategy is to target large pharmaceutical companies and build on the success so far with AstraZeneca and Bristol Myers. The current installed base is 22 units. Key catalysts include announcements around expansion of additional orders within the customer base and orders from new customers.

Sticker shock offers an opportunity

Car Group
3:27pm
February 10, 2025
CAR 1H25 result was resilient, with pro forma revenue growth of 9-30% across its key markets. However, it was the slight miss vs consensus at EBITDA and the deferral in putting through a price rise in the US business that saw the stock trade lower on the day, in our view. We make minor changes to our FY25-FY27F EBITDA (-1%/-+1%) on the result and guidance update. Our price target increases to A$41.40 on the above changes, an uplift to our longer-term margin assumptions and a DCF valuation roll-forward. Given ~10% TSR upside to our price target, we move to an Add recommendation.

1H beat- looks like a growth stock . . . but it’s not

Ansell
3:27pm
February 10, 2025
1H was better than expected, with strong, double-digit top and bottom line growth, but was mainly supported by acquisition gains, cost outs and one off items. Industrial sales and margins both improved on new product introductions and higher pricing, while Healthcare jumped on normalistion from channel inventory destocking and slowed production. While stocking/restocking appear “neutral” and guidance upgraded c4% at the mid-point, we remain cautious, given Healthcare’s easy gains are now limited, KBU is entering a transition period with risk of sales leakage and customer disruptions, and price increases and cost outs need to offset higher input costs and tariffs. FY25-27 EPS increases 5%, with our DCF/SOTP PT increasing to A$33.38. Hold.

1H25 Earnings: Sales perks

JB Hi-Fi
3:27pm
February 10, 2025
JBH has produced another solid result for the first half, and was ahead of consensus expectations. Sales momentum accelerated in the 2Q driven by demand for tech and consumer electronic products, and has continued into the start of the 2H. Margins were managed better than we expected given the highly promotional and competitive environment, and ongoing cost pressures. We have increased our revenue forecast as a result of strong sales momentum, which has flowed through to 3.5%/4% increase in NPAT in FY25/FY26. We have increased our TP to $92 from $87, but see the current valuation of ~23x FY26 P/E as too expensive, given its 10 year average is ~14x. We retain our HOLD recommendation. With this note, lead coverage of JB Hi-Fi passes to Emily Porter.

Strategic review is key

MedAdvisor
3:27pm
February 10, 2025
Last November, MDR announced a strategic review to help restore value to the business which has seen the market capitalisation fall over 65% since June 2024. The outcome of the review is expected to be announced in 3Q25. The 2Q25 cashflow reported lower revenue and margins than the previous corresponding period. Reflecting the lower than expected US flu vaccination rates. Management has guided to a positive EBITDA for FY25 (consensus A$2.0m). The consensus mean target price is A$0.25.

Still undercooked but getting there

Domino's Pizza
3:27pm
February 7, 2025
DMP’s now regular pre-reporting trading update was better than feared with underlying PBT in line with consensus and no major change/reset of the business announced which was widely expected. New management have so far identified A$34.1m of annualised EBIT savings for the DMP network with more to come. Given the review of the cost base is continuing, DMP has yet to determine both the size of the total savings pool and how it plans to balance how much of the savings will flow to its franchise network (to lift unit economics) vs its own bottom line. Management indicated on the conference call that in the near-term, a greater weighting of savings would likely be reinvested in the network to lift unit economics and reignite organic growth. DMP is making positive steps in the right direction, in our view. However, the key for us to turn positive is a clearer picture on what future organic top line growth will look like going forward. HOLD maintained. As part of the trading update, DMP announced A$34.1m of annualised savings with more to come. Part of these savings (A$15.5m EBIT) is the closure of 205 loss-making stores occurring in the 4Q25. 172 (58 Franchise and 114 Corporate) of those store closures will be in Japan. DMP will incur a one-off impact of A$97.2m in FY25 for these closures (A$37.4m cash impact). Management said in the call that it believes the store network has now been right-sized for future growth and doesn’t expect any future store closures. DMP has also identified A$18.6m of annualised savings associated with simplifying the network and the cost base and identifying opportunities to buy better and spend better in areas including food, packaging, and technology. Given the review of the cost base is continuing, DMP has yet to determine both the size of the total savings pool and how it plans to balance how much of the savings will flow to its franchise network (to lift unit economics) vs its own bottom line. At the FY24 result, on our estimates, DMP needed to lift average sales per store (referring to its franchise partner dashboard reported at FY24) by ~10% to achieve the desired 3 year payback. This would’ve taken ~3 years to achieve. We think the right move is for any cost savings to be reinvested in the franchise network so that the 3 year payback period is achieved sooner rather than later. DMP plans to provide a more detail update on its turnaround strategy at an Investor Day in 2H25.

Expanding its pool of Brown Label ATM customers

Findi
3:27pm
February 7, 2025
FND has announced a new Brown Label ATM (BLA) agreement with Union Bank of India (UBI). The contract is for 7+ years and will deliver A$75m-A$80m of total revenue and A$33m-A$38m of EBITDA over the contract life. The deal is obviously a positive, in our view, noting it both diversifies FND’s BLA customer base, whilst also being strongly value accretive. We upgrade our FND FY25F/FY26F/FY27F EPS by >10% (off low bases) on both incorporation of the UBI deal into our numbers, and some tweaking of our broader earnings forecasts. Our PT is set at A$7.68 (previously A$7.17). FND management appear to be executing well on the company’s overall build out, and with +50% upside to our blended valuation (A$7.68) we maintain our ADD call.

News & Insights

Michael Knox, Chief Economist, reveals how the OECD and RBA’s outdated assumptions about global trade fail to account for China’s Marxist-Leninist economic strategies.

This morning, I was asked to discuss Sarah Hunter’s presentation from yesterday. Sarah, the Assistant Governor and Chief Economist at the Reserve Bank of Australia (RBA), delivered a detailed and competent discussion on the conventional view of tariffs’ impact on the international economy. She highlighted that tariffs typically increase inflation and reduce economic output, a perspective echoed by the OECD in a similar presentation overnight. Sarah’s analysis focused on the potential shocks tariffs could cause, particularly their effects on GDP and inflation.

Drawing on my experience as an Australian trade commissioner and my work in Australian embassies, I found her presentation particularly interesting. My background allowed me to bring specialist knowledge to the conversation, which I believe gave me an edge. Notably, I observed that the RBA seems to lack analysts closely tracking individual policymakers in the Trump administration, such as Scott Bessent, whose views on tariffs and competition differ from the general assumptions. The conventional view assumes a world of perfectly competitive countries adhering to international trade rules and unlikely to engage in conflict—a scenario that doesn’t align with the current global trade environment, especially between China and the United States.

China, operating as a Marxist-Leninist economy, aims to dominate global markets by building monopolies in areas like rare earths, nickel, copper, and other base metals. It maintains a managed exchange rate, despite promises to the International Monetary Fund for a freely floating currency. If China allowed its currency, the RMB, to float, it would likely appreciate significantly, increasing imports and reducing its trade surplus. This would create a more balanced international trade environment, potentially reducing the need for other countries to impose tariffs. However, major institutions like the OECD and RBA seem to misjudge the nature of this trade shock, relying on outdated assumptions about global trade dynamics.

The international community also appears to overlook specific U.S. policy intentions, such as those articulated by figures like Peter Navarro and Scott Bessent. The U.S. aims to use tariffs selectively to bolster industries like pharmaceuticals, precision manufacturing, and motor vehicles. This misunderstanding leads public institutions to perceive unspecified risks, as reflected in Sarah’s otherwise able presentation. Because the RBA and similar institutions view the world as fraught with undefined risks, they are inclined to keep interest rates low, responding to perceived threats rather than an equilibrium model.

Interestingly, data from the U.S. economy contradicts the expected negative impacts of tariffs. The Chicago Fed National Activity Indicator, a reliable gauge of economic growth since the 2008 financial crisis, shows U.S. growth above the long-term trend for the first four months of this year. This suggests resilience despite tariff-related shocks. Ideally, growth will slow later this year, prompting the Federal Reserve to cut rates, facilitating a soft landing and a decline in the U.S. dollar to boost global commodity prices. However, this nuanced outlook wasn’t evident in yesterday’s presentation.

Moreover, the anticipated rise in U.S. inflation due to tariffs isn’t materialising. Scott Bessent recently noted that U.S. CPI inflation is lower than expected, with core inflation shown as the (16% trimmed mean) at 3% for the past two months . Core inflation  excluding  food and energy CPI  is only at 2.8%. This suggests that Chinese suppliers are absorbing tariff costs to maintain market share, rather than passing them on as higher prices. Recent Chinese data supports this, showing a slight decline in manufacturing confidence and coal consumption, indicating reduced factory output and electricity use. This points to a modest slowdown in China’s economy. So far the expected negative effects on U.S. prices and output are not occurring.

In summary, the fears expressed by institutions like the RBA and OECD about the Trump administration’s trade policies appear overstated. The U.S. economy is not experiencing the predicted declines in output or increases in inflation. While these effects may emerge later, the current data suggests that the risks are not as severe as anticipated, highlighting a disconnect between theoretical models and real-world outcomes.

Read more
Michael Knox outlines the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and his own analysis for Australia.

Today, I’m presenting the first page of my updated presentation, which focuses on GDP growth and inflation expectations for major economies. Before diving into that, I want to clarify a point about U.S. trade negotiations that has confused some media outlets.

In the previous Trump Administration ,there was single trade negotiator, Robert Lighthizer, held a cabinet position with the rank of Ambassador. This time, to expedite negotiations and give them more weight, Trump has appointed two additional cabinet-level officials to handle trade talks with different regions. For Asian economies, Scott Bessent and Ambassador Jamison Greer, who succeeded Lighthizer and previously served on the White House staff, are managing negotiations, including those with China. For Europe, Howard Lutnick, the Commerce Secretary, and Ambassador Greer are negotiating with the European Trade Representative. When the EU representative visits Washington, D.C., they meet with Lutnick and Greer, while Chinese or Japanese representatives engage with Bessent and Greer.

In my presentation today, I’m outlining the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and my own analysis for Australia.

For the U.S., the best-case scenario is a soft landing, with growth slowing but remaining positive at 1.3% this year and rising to 1.7% next year. This slowdown allows the Federal Reserve to continue cutting interest rates, leading to a decline in the U.S. dollar. This in turn ,triggers a recovery in commodity prices. These prices have stabilized and are now trending upward, with an expected acceleration as the dollar weakens.

U.S. headline inflation is projected to be just below 3% next year, with higher figures this year driven by tariff effects.



Global Economic Perspective

In the Euro area, growth is accelerating slightly, from just under 1% this year to 1.2% next year, with inflation expected to hit the 2% target this year and dip to 1.9% next year.

China’s GDP growth is forecast  at 4% for both this year and next, a step down from previous 5% rates, reflecting a significant slump in domestic demand and very low inflation  Chinese Inflation is only  :   0.2% last year, 0.4% this year, and 0.9% next year.  Despite a massive fiscal push, with a budget deficit around 8% of GDP, China’s debt-to-GDP ratio is rising faster than the U.S.. Yet this is  yielding more modest  domestic growth.

India, on the other hand, continues to outperform, with 6.5% GDP growth last year, 6.2% this year, and  6.3%  next year, surpassing earlier projections.

Read more
In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia.

Positive earnings surprise

In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia. For all the volatility in markets caused by US trade policy, the results were positive. For all the 187 high profile and blue-chip companies in our International Watchlist, the median EPS beat vs consensus was 3.2%, nearly twice that recorded in the December quarter (1.8%). 37% of companies exceeded consensus EPS expectations by more than 5% and only 9% missed by more than 5%. Communication Services was the most positive sector, led by Magnificent 7 companies Alphabet and Meta Platforms. The median EPS beat in that sector was 13%. Consumer Discretionary was the biggest disappointment (though only a mild one) with EPS falling 0.6% short of analyst estimates on a median basis.

Alphabet and Meta among the best performers

Across our Watchlist, some of the best performing stocks in terms of EPS beats were Alphabet, Boeing, Uniqlo-owner Fast Retailing, Meta Platforms, Newmont and The Walt Disney Company. Notable misses came from insurance broker Aon, BP, PepsiCo, Starbucks, Tesla and UnitedHealth. The latter saw by far the worst share price performance over reporting season, its earnings weakness compounded by the resignation of its CEO and the launch of a fraud investigation by the Department of Justice. British luxury fashion label Burberry had the best performing share price as it gains traction in its turnaround plan.

Tariffs were the main talking point (of course)

The timing of President Trump’s ‘Liberation Day’ on 2 April, just before the March quarter results started rolling in, guaranteed that US tariffs would be the main talking point throughout reporting season. Most companies took the line that higher tariffs presented a material risk to global growth and inflation. The rapidly shifting sands of US trade policy mean the impact of tariffs is highly uncertain. This didn’t stop many companies from trying to estimate the impact on their profits. This ranged from the very precise ($850m said RTX) to the extremely vague (‘a few hundred million dollars’ hazarded Abbott Laboratories). The rehabilitation of AI as a systemic driver of long-term value was a key theme of reporting season, with many companies reporting what Palantir Technologies described as an ‘unstoppable whirlwind of demand’ and others indicating an increase in planned AI investment. The deterioration in consumer confidence was another key talking point, though most companies could only express concern about a possible future softening in demand rather than any actual evidence of a hit to sales.

Our International Focus List continues to outperform

In this report, we also report on the performance of the Morgans International Focus List, which is now up 25.3% since inception last year, outperforming the benchmark S&P 500 by 20.4%.


Morgans clients receive exclusive insights such as access to our latest International Reporting Season article.

Contact us today to begin your journey with Morgans.

      
Contact us
      
      
Find an adviser
      
Read more